88 results about "Motor disorder" patented technology

A method for treating spasticity of a subject is provided, including driving a current into a nerve of the subject that includes one or more sensory fibers, and configuring the current so as to inhibit propagation of action potentials in one or more of the sensory fibers, so as to treat the spasticity. In a preferred embodiment, the sensory fibers include one or more Ia sensory fibers, and configuring the current includes configuring the current so as to inhibit propagation of the action potentials in at least one of the Ia sensory fibers.

A process and device for treating obesity and syndromes related to motor disorders of the stomach of a patient is provided. The process includes artificially altering, by means of electrical pulses for preset periods of time, the natural gastric motility of the patient to prevent the emptying of or to slow down gastric transit through the stomach to increase the feeling of satiety and / or to accelerate intestinal transit to reduce absorption time within the intestinal tract. More specifically, the electrical stimulation induces tachygastria, which inhibits gastric motility, yields gastric distention, and delays gastric emptying. The tachygastrial electrical stimulation of the stomach, or other portions of the gastrointestinal tract, includes relatively long pulse widths, with lengths of up to 500 milliseconds.

The invention relates to the improvement in the treatment of certain neural disorders / diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.

The present invention describes a series of therapeutically active compounds of formula I,X—Y—Z  (I)that are useful for treating a disorder in a mammal. In the formula I, X and Z, which may be same or different, are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic group or substituted or unsubstituted heterocyclylalkyl; and Y is a linker selected from —O—, —S—, —NH—, —(CH2)n—, —CO—, —CONRa—, —NRaCO—, —NRaCOO—, —COO—, —CONRaCO—, —CONRaCOO— and —COOCOO—. The compounds are useful to treat neurodegenerative disorders, depression, Alzheimer's disease, cognitive disorders, motor disorders, Parkinson's disease, drug addiction, behavioral disorders, inflammatory disorders, stomach disorders, cancers, acute pain, chronic pain and recurrent pain.

A method for using spinal cord stimulation to treat symptoms of motor disorders includes implanting a stimulation lead within a ventral portion of the epidural space. The lead is implanted with at least a portion of the electrodes facing the spinal cord. In a method for providing therapy to a patient suffering from a motor disorder, electrical stimulation energy is applied to at least one ventral column nerve fiber through the implanted stimulation lead. A peripheral region of the patient's body exhibits the symptoms of the motor disorder, and the ventral column nerve fiber to which the stimulation is applied innervates that peripheral region.

A method for treating spasticity of a subject is provided, including driving a current into a nerve of the subject that includes one or more sensory fibers, and configuring the current so as to inhibit propagation of action potentials in one or more of the sensory fibers, so as to treat the spasticity. In a preferred embodiment, the sensory fibers include one or more Ia sensory fibers, and configuring the current includes configuring the current so as to inhibit propagation of the action potentials in at least one of the Ia sensory fibers.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful NI for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

An apparatus for rehabilitation of patients with motor disorders affecting the legs and standing dysfunctions, the apparatus comprising a couple of bars moving along a closed loop representing a walking step for the patient, with each bar including a plate to affix a foot of the patient and the plate being slidably arranged in the bar, with a motor connected to the bars to move the bars along the closed loop, the apparatus also having an harness to support the patient.

The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and / or tremor associated with Parkinson's disease.

The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and / or tremor associated with Parkinson's disease.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention relates to an aporphine compound represented by general formula (I) or stereoisomer thereof, pharmaceutically acceptable salt or pharmaceutically acceptable solvate and medical application thereof. The compound can be used for preventing or treating diseases related with serotonin 1A receptors, wherein the diseases comprise central nervous system diseases, in particular schizophrenia, depression and movement disorder caused by Parkinson's resistant medicament. The invention also relates to a medicinal composition comprising the compound.

A method for using spinal cord stimulation to treat symptoms of motor disorders includes implanting a stimulation lead within a ventral portion of the epidural space. The lead is implanted with at least a portion of the electrodes facing the spinal cord. In a method for providing therapy to a patient suffering from a motor disorder, electrical stimulation energy is applied to at least one ventral column nerve fiber through the implanted stimulation lead. A peripheral region of the patient's body exhibits the symptoms of the motor disorder, and the ventral column nerve fiber to which the stimulation is applied innervates that peripheral region.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.

The invention relates to a system and method for measuring the biomechanical state of a subject using various sensors simultaneously with providing the subject with visual exercises for rehabilitation and assessment of disequilibrium, balance and motion disorders. The biomechanical state of a subject is measured during the subject's performance of a predetermined task. Such measurements are useful for the assessment of disequilibrium, balance and motion disorders and are also useful for the determination of therapeutic application of vibrotactile, auditory, or visual feedback to a subject during the subject's attempt to perform a predetermined task. An intelligent controller compares the subject's biomechanical state to a predetermined parameter to determine a variance. If the variance exceeds a threshold, feedback in the form of visual feedback, vibrotactile feedback or auditory feedback may be provided to the subject as a therapeutic means for enabling the subject to compensate for disorder effects.

The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for usein the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, 5 amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.

The invention relates to the selective targeting of specific α2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the α2c receptor subtype using an α2c specific agonist or by blocking the α2a receptor subtype using α2a antagonists. A combination of an α2c agonist and an α2a antagonist is also provided for a synergistic effect. Alternatively, a large α2 agonist can be used in combination with an α2a antagonist to achieve specific stimulation of the α2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists / antagonists as active agents are objects of the present invention. A robotic interface and epidural electric stimulation can also be used in combination with the compositions of the invention for restoring voluntary control of locomotion.

The invention relates to a method and system for generating handwritten text with different degrees of maturity of the writer without needing to have the original text of the writer, thereby allowing the generation of text online (synthesizing temporal movement) and offline (generating the image of the handwriting), the simulation of real development in terms of the number of strokes and the velocity profile of the writer according to his or her progress, and the generation of handwriting of writers with possible neurological and motor disorders.

The present invention provides a system and a method for detecting a neuromotor disorder or condition in a subject using an electronic device that comprises an input device. The method generally involves determining input device usage characteristics of the subject and comparing the result to a reference input device usage characteristic.

4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a FAAH modulator. 4-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is also disclosed.

The present invention refers to a system for stimulation of the spinal cord for the rehabilitation of motor function in subjects with spinal cord injury or other motor disorders. Said system comprises a programmable implantable pulse generator (IPG), operatively connected to deliver current pulses to one or more multi-electrode arrays, wherein said IPG is adapted to deliver to said multi-electrode array a stimulation characterized by a frequency comprised between 20 and 1200 Hz and an amplitude comprised between 0.1 motor threshold amplitude and 1.5 motor threshold amplitude. The use of such system for facilitating locomotor functions or upper limb movements in a subject with neuromotor impairments is also within the scope of the invention.

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention provides methods utilizing ketamine for the treatment of motor disorders and / or side effects associated with certain medications used in the treatment of motor disorders. For example, in some embodiments, methods are provided for treating side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering a dose of ketamine or a pharmaceutically acceptable salt thereof. In particular, the invention provides methods for reducing dyskinesia associated with motor disorder (e.g., Parkinson's disease) treatments, and effective doses of ketamine or a pharmaceutically acceptable salt thereof.

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

The present invention refers to a system for stimulation of the spinal cord for the rehabilitation of motor function in subjects with spinal cord injury or other motor disorders. Said system comprisesa programmable implantable pulse generator (IPG), operatively connected to deliver current pulses to one or more multi-electrode arrays, wherein said IPG is adapted to deliver to said multi-electrodearray a stimulation characterized by a frequency comprised between 20 and 1200 Hz and an amplitude comprised between 0.1 motor threshold amplitude and 1.5 motor threshold amplitude. The use of such system for facilitating locomotor functions or upper limb movements in a subject with neuromotor impairments is also within the scope of the invention.